AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Jupiter Neurosciences, Inc.
Video analysis: JUNS
All videosNo video analysis for this stock yet. Request one from our team.
News: JUNS
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2M. D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about August 24, 2026, subject to the satisfaction of customary closing conditions.
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson's disease program
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth
